UCB has announced new three-year data for BIMZELX (bimekizumab) in moderate to severe hidradenitis suppurativa (HS), showing sustained disease control and symptom resolution across the most stringent clinical endpoints. Bimekizumab is the first approved treatment to selectively inhibit interleukin 17A and 17F. Quality of life improvements were also maintained, with 38.1% reporting no impact of skin disease. Patients achieving IHS4-100 at year one sustained complete resolution of inflammatory lesions through to year two in 64.3% of cases. John Ingram, Professor of Dermatology, Cardiff University, said: “These data for bimekizumab – including HiSCR100 and IHS4-100 – showed disease control can be maintained long-term.